Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | TARDBP | Q13148 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.66 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioctic Acid Amide SCHEMBL4380181 | 0.94 | KMT2A (1.00) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| Thioctic Acid Amide SCHEMBL41833 | 0.94 | KMT2A (1.00) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| Thioctic Acid Amide SCHEMBL50599 | 0.94 | KMT2A (1.00) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| Thioctic Acid Amide SCHEMBL13093778 | 0.94 | KMT2A (1.00) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| Thioctic Acid Amide SCHEMBL28076123 | 0.93 | KMT2A (0.96) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| SCHEMBL27494633 | 0.93 | KMT2A (0.96) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| Thioctic Acid Amide SCHEMBL16653981 | 0.93 | KMT2A (0.96) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| SCHEMBL29249630 | 0.93 | KMT2A (0.96) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| SCHEMBL7842547 | 0.90 | KMT2A (0.73) | KMT2ATARDBPHSD17B10CYP2C9MEN1 | |
| Thioctic Acid Amide SCHEMBL3400641 | 0.88 | KMT2A (0.87) | KMT2ATARDBPHSD17B10CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653668-B2 | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | OP2 Drugs (FR) | 2020-05-19 | — | — | US | disclosed |
| US-20190274997-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10272066-B2 | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | UNIVERSITÉ DE BORDEAUX (FR) | 2019-04-30 | — | — | US | disclosed |
| WO-2017042267-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | ORPHAN PARTNERS 2 (FR) | 2017-03-16 | — | — | WO | disclosed |
| US-20150031701-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | ZPNE GROUP GMBH (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150031701-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | ZPNE GROUP GMBH (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20130259930-A1 | Compositions and Methods for Preventing and Treating Mucositis and Weight Loss | CASCADE ESTATE LTD. (MU) | 2013-10-03 | — | — | US | disclosed |
| US-20130259930-A1 | Compositions and Methods for Preventing and Treating Mucositis and Weight Loss | CASCADE ESTATE LTD. (MU) | 2013-10-03 | — | — | US | disclosed |
| US-20120196825-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | SUPPORTIVE THERAPEUTICS AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20120196825-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | SUPPORTIVE THERAPEUTICS AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20100092547-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | ZPNE GROUP GMBH (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100092547-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | ZPNE GROUP GMBH (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20090156546-A1 | Compositions and methods for modulating the immune system | SUPPORTIVE THERAPEUTICS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156546-A1 | Compositions and methods for modulating the immune system | SUPPORTIVE THERAPEUTICS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| WO-2008110585-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | PRENDERGAST PATRICK T (AU) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007131973-A2 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | PRENDERGAST PATRICK T (AU) | 2007-11-22 | — | — | WO | disclosed |
| US-6313164-B1 | TO ENHANCE THE ACTIVITY OF GLUTATHIONE RECLUCTASE; FOR THERAPY AND PROPHYLAXIS OF CARTARACTS | SANKYO COMPANY, LIMITED (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1070710-A2 | Dithiolan derivatives, their preparation and their therapeutic effect | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-6013663-A | CATARACT THERAPY OR PREVENTION | SANKYO COMPANY, LIMITED (JP) | 2000-01-11 | — | — | US | disclosed |
| EP-0869126-A1 | Dithiolan derivatives, their preparation and their therapeutic effect | Sankyo Company Limited (JP) | 1998-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092547-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | MTAP, TPMT, MUC1 | KMT2A 1469/4885TARDBP 4019/4885HSD17B10 3624/4885 |
| US-20150031701-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | SI, MTPN, MUC1 | KMT2A 2229/4885TARDBP 1824/4885HSD17B10 764/4885 |
| US-10653668-B2 | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | FH, TXNRD2, TXN2 | KMT2A 3925/4885TARDBP 485/4885HSD17B10 381/4885 |
| US-20130259930-A1 | Compositions and Methods for Preventing and Treating Mucositis and Weight Loss | SI, MTPN, MUC1 | KMT2A 2229/4885TARDBP 1824/4885HSD17B10 764/4885 |
| US-20190274997-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION | FH, TXNRD2, TXN2 | KMT2A 3925/4885TARDBP 485/4885HSD17B10 381/4885 |
| US-20090156546-A1 | Compositions and methods for modulating the immune system | MRE11, XPA, MPL | KMT2A 1389/4885TARDBP 4624/4885HSD17B10 3484/4885 |
| US-10272066-B2 | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | FH, TXNRD2, TXN2 | KMT2A 3925/4885TARDBP 485/4885HSD17B10 381/4885 |
| US-20120196825-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM | MRE11, XPA, MPL | KMT2A 1389/4885TARDBP 4624/4885HSD17B10 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.